Fosun Pharma unit Henlius signs licensing deal with Amberstone for T-cell engager products
On September 23, 2026, Shanghai Henlius Biotech, a subsidiary of Fosun Pharma, signed a collaboration and license agreement with Amberstone for two T-cell engager (TCE) products. Henlius receives an exclusive global license to research, develop, manufacture, and commercialize the products using Amberstone's T-MATE™ platform. Henlius will pay up to $236.16 million in upfront fees, R&D costs, and milestone payments, plus up to $652 million in sales milestones, with additional royalties.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
Fosun Pharma Subsidiary Signs Exclusive License Deal with Amberstone for T-Cell Engager Products
On September 23, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its subsidiary, Henlius, has entered into a Collaboration and License Agreement with Amberstone. Under the agreement, Henlius obtains an exclusive global license to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting specific tumor antigens, using Amberstone's proprietary T-MATE™ technology platform. The T-MATE™ platform is a tumor microenvironment-activated technology designed to enhance the selective targeting of TCE molecules to tumor tissues while reducing effects on normal tissues, potentially addressing the narrow therapeutic window and safety limitations of traditional TCE products in solid tumor treatment. The collaboration focuses on two targets designated by Henlius for oncology applications.
Fosun Pharma unit Henlius gets exclusive license from Amberstone for up to $236 million
On September 23, 2026, Fosun Pharma announced that its controlling subsidiary Shanghai Henlius Biotech has entered into a Collaboration and License Agreement with Amberstone. Under the deal, Henlius receives an exclusive worldwide license for all human uses to research, develop, manufacture, and commercialize two collaboration products targeting a specified target, based on Amberstone's T-MATE™ technology platform. Henlius will pay Amberstone up to $236.16 million in upfront fees, R&D expenses, and development and regulatory milestones, including an upfront payment of up to $4 million and up to $232.16 million in R&D and regulatory milestones tied to PCC, clinical studies, regulatory approvals, and launch progress. Additionally, Henlius may pay up to $652 million in tiered sales milestone payments based on annual net sales of the collaboration products in the licensed territory.
Fosun Pharma unit Henlius gets exclusive license from Amberstone in deal worth up to $236 million
Fosun Pharma announced on September 23 that its subsidiary Henlius has signed a Cooperation and License Agreement with Amberstone. Under the agreement, Henlius receives an exclusive global license for all human uses to research, develop, produce, and commercialize two products based on Amberstone's T-MATE™ technology platform for a specified target. Henlius will pay Amberstone up to $236.16 million in upfront fees, R&D costs, and development and regulatory milestones, including an upfront payment of up to $4 million and combined R&D and milestone payments of up to $232.16 million, contingent on progress in R&D, preclinical candidate selection, clinical studies, regulatory approvals, and market launches. Additionally, Henlius will pay Amberstone up to $652 million in tiered sales-based milestone payments based on annual net sales of the products in the licensed territory.
Read sourceShow 3 older updatesHide older updates
Fosun Pharma Subsidiary Henlius Signs Global License Deal with Amberstone for T-Cell Engager Products
On September 23, 2026, Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, has entered into a Collaboration and License Agreement with Amberstone. Under the agreement, Henlius obtains an exclusive global license, for all human uses, to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting two undisclosed tumor antigens. The products will be designed using Amberstone's proprietary T-MATE technology platform, a tumor microenvironment-activated platform that modulates TCE molecule activation in the tumor microenvironment versus peripheral tissues. This approach aims to enhance selective targeting of tumor tissues and reduce impact on normal tissues, potentially addressing the narrow therapeutic window and safety limitations of traditional TCE products in solid tumor treatment.
Read sourceHenlius and Amberstone Sign TCE Collaboration and License Agreements
Shanghai Henlius Biotech announced on September 23, 2026, that it has entered into collaboration and license agreements with Amberstone for two T-cell engager (TCE) products based on the T-MATE technology platform. Under the agreements, Amberstone grants Henlius an exclusive sublicensable license for early-stage research and development targeting two specific targets designated by Henlius. The total research and development costs, along with development and regulatory milestone payments, are capped at $232 million. Sales milestone payments could reach up to $652 million, with additional royalty payments at a low single-digit percentage of annual net sales. The partnership covers global research, development, manufacturing, and commercialization of the two TCE products.
Read sourceFosun Pharma unit Henlius signs licensing deal with Amberstone for T-cell engager products
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced on September 23 that its controlling subsidiary, Shanghai Henlius Biotech, has entered into a collaboration and license agreement with Amberstone. The agreement grants Henlius an exclusive, worldwide license for all human therapeutic uses to develop, manufacture, and commercialize two T-cell engager products targeting a designated antigen, based on Amberstone's T-MATE technology platform. Under the terms, Henlius will pay up to $236 million in upfront fees, R&D expenses, and development and regulatory milestone payments, plus up to $652 million in sales milestone payments. The announcement was reported by Jiemian News and carried on East Money's A-share company news feed.
Read source